It is consistent with the hypothesis that in response to PARP inhibitor therapy or platinum chemotherapy, the tumor acquired a mechanism to activate HR despite retaining BRCA1 deficiency, which can then be blocked with ATR inhibition. The gene discussed is BRCA1; the disease is neoplasm.